US FDA Implements 'Firm-Based' Regulatory Approach To DTC Genetic Health Risk Tests

Formalizing an approach applied to oversight of 23AndMe's direct-to-consumer genetic health risk tests, US FDA Nov. 6 said it plans to allow DTC testing services to be exempted from pre-market review after each individual maker of such an offering comes to the agency for a one-time review to ensure it meets FDA requirements.

US FDA said Nov. 6 it is implementing a novel "firm-based regulatory approach" to overseeing consumer genetic health risk (GHR) tests that it initiated in April when it allowed 23andMe Inc., to launch the first FDA-validated direct-to-consumer tests predicting individuals' predisposition to genetic diseases and conditions.

The April 6 determination paved the way for FDA's formalization this week of its de novo classification of GHRs as class II devices. In parallel, the agency proposed...

More from Regulation

More from Policy & Regulation